Figure 4
Figure 4. High-dimensional mass cytometry of diagnosis and relapse specimens. (A) The viSNE maps of diagnosis and relapse specimens, as defined by cell surface antigens. High-dimensional mass cytometry was performed on 3 cases (AML1, AML5, and AML22) at diagnosis and relapse, where functional LSC expansion was identified by LDA. viSNE analysis was employed to display the single cell data results, using data from 14 separate cell surface antigens with a Jensen-Shannon Divergence score for pairs AML1, 0.67531; AML5, 0.6808; and AML22, 0.67365. These data indicate the large measurable changes in cellular physiology between diagnosis and relapse for the total mononuclear cell population. (B) The viSNE maps of functionally defined LSC populations at diagnosis and relapse; specimens as defined by cell surface antigens.

High-dimensional mass cytometry of diagnosis and relapse specimens. (A) The viSNE maps of diagnosis and relapse specimens, as defined by cell surface antigens. High-dimensional mass cytometry was performed on 3 cases (AML1, AML5, and AML22) at diagnosis and relapse, where functional LSC expansion was identified by LDA. viSNE analysis was employed to display the single cell data results, using data from 14 separate cell surface antigens with a Jensen-Shannon Divergence score for pairs AML1, 0.67531; AML5, 0.6808; and AML22, 0.67365. These data indicate the large measurable changes in cellular physiology between diagnosis and relapse for the total mononuclear cell population. (B) The viSNE maps of functionally defined LSC populations at diagnosis and relapse; specimens as defined by cell surface antigens.

Close Modal

or Create an Account

Close Modal
Close Modal